Treace Medical Concepts, Inc. Earnings Call Transcript
TMCI Stocks , Present from the company today will include John Treace, chief executive officer, as well as Mark Hair, chief financial officer. During the conference we will provide a briefing about our commercial operations and will review our financial results for the first quarter that were released following the close of the market today, following which we will hold an open-ended question and answer session.
The press release can be found in the Investor Relations section of our website at newsfinancial.info The call will be recording and archived on the section for investors on our website. Before we start we want be sure to inform you that we have a plan to ensure that all forward-looking information made during the call will be covered under the Private Securities Litigation Reform Act of 1995. All statements that are based on anticipations or expectations of future events or market trends, or our expectations of our performance or results are forward-looking statements.
These statements are based on our current estimates and other assumptions. They are subject to uncertainties and risks that could result in actual results or events to be different from the expectations or predictions made from these forecasts or statements. These statements are based on the most the most current information available, and Treace is not under any obligation to make any changes to the statements. As such you should not put too much reliance on the statements.
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $88.55M | -19.1% |
| Accounts Receivable | $18.55M | +57.3% |
| Inventory | 16.794 | +62.2% |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $71.66M | +144.4% |
| Short Term Debt | $0.33M | – |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -30.6% | – |
| Return On Invested Capital | -16.0% | +2.4% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$14.06M | +37.8% |
| Operating Free Cash Flow | -$8.20M | -11.5% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 10.10 | 11.01 | 9.13 | 17.05 | +23.6% |
| Price to Sales | 10.70 | 9.90 | 6.95 | 9.75 | -41.6% |
| Price to Tangible Book Value | 10.10 | 11.01 | 9.13 | 17.05 | +23.6% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -175.43 | -126.64 | -71.37 | -120.51 | -52.6% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -43.8% | -63.1% | -45.0% | -56.4% | – |
| Total Debt | $29.37M | $44.67M | $70.76M | $71.99M | +145.5% |
